Phaseline

Companies › Changzhou Qianhong Bio-pharma

Changzhou Qianhong Bio-pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QHRD106 Injection–Phase 2Acute Ischemic StrokeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07396337QHRD106 InjectionPhase 2Acute Ischemic StrokeNeurologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.